Table 2. Selected treatment-related adverse events in patients with anlotinib or placebo according to EGFR mutation status.

Event	EGFR M+ (n=138) (%)						EGFR M− (n=299) (%)
	Anlotinib (n=93)			Placebo (n=45)			Anlotinib (n=201)			Placebo (n=98)
	Any grade	Grade 3–4		Any grade	Grade 3–4		Any grade	Grade 3–4		Any grade	Grade 3–4
Hypertension	60 (64.5)	9 (9.7)		5 (11.1)	0		130 (64.7)	30 (14.9)		15 (15.3)	0
Elevated thyroglobulin	49 (52.7)	0		0	0		82 (40.8)	1 (0.5)		6 (6.1)	0
Hand and foot syndrome	45 (48.4)	2 (2.2)		4 (8.9)	0		82 (40.8)	9 (4.5)		9 (9.2)	0
Elevated triglyceride	39 (41.9)	3 (3.2)		7 (15. 6)	0		75 (37.8)	4 (2.0)		20 (20.4)	0
Proteinuria	25 (26.9)	2 (2.2)		4 (8.9)	1 (2.2)		52 (25.9)	5 (2.5)		15 (15.3)	0
Rash	7 (7.5)	0		2 (4.4)	0		27 (13.4)	0		6 (6.1)	1 (1.0)

EGFR, epidermal growth factor receptor; M+, mutation positive; M−, mutation negative.